BERKELEY, Calif., May 8 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (OTC Bulletin Board: NILT.OB), a biopharmaceutical company focused on developing therapies for cardiovascular disease, is pleased to announce the appointment of Jane Moffitt, J.D., LL.M. as its Vice President of Regulatory Affairs.
"We believe Jane's specific leadership contribution to the launch and development of natriuretic peptide BNP, Natrecor(R), plus her extensive regulatory affairs background will be of great value to Nile as we develop our own natriuretic peptide, CD-NP and cardiovascular pipeline," said Peter Strumph, Chief Executive Officer of Nile.
Ms. Moffitt has over 30 years of professional experience in regulatory affairs and corporate and food & drug law for pharmaceutical, device and biotechnology companies. This experience includes developing clinical regulatory strategies and leading teams responsible for preparing and maintaining INDs, NDAs, BLAs and global product launches. Her drug product expertise includes natriuretic peptides, small molecules and biologics.
Prior to joining Nile, Ms. Moffitt was the West Coast Director of Operations for SciLucent, a specialty healthcare-focused consulting firm. Prior to that, Jane was a Senior Vice President of Quality and Regulatory Affairs at a number of pharmaceutical and medical device companies, including Revance Therapeutics Inc., Scios, Inc., Collagen Corporation, and Amsco International Inc., and worked as a corporate attorney at Miles Laboratories, Inc. At Scios, Ms. Moffitt was a member of the Corporate Management Committee, started the Government Affairs function and was the head of the regulatory affairs function. Ms. Moffitt also served as President, Treasurer and a member of the Board of Directors of Scios R&D, Inc. and BRP, Inc.
Ms Moffitt holds a B.S. in Biology and Political Science from Dickinson
College, a J.D. from Dickinson School of Law and a LL.M. in Trade
Regulation from New Y
|SOURCE Nile Therapeutics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved